Cerapedics Adds New Board Member
Antony Koblish, CEO of Tela Bio and former CEO of Orthovita, to join board
WESTMINSTER, Colo. -- March 12, 2013
Cerapedics, Inc. today announced that Antony Koblish, president and CEO of
privately-held Tela Bio, Inc. and former CEO of Orthovita, Inc., was appointed
to the Company’s board of directors.
“Tony has extraordinary industry expertise and operational knowledge and we
are delighted that he is joining Cerapedics’ board of directors,” said
Jonathan Silverstein, Cerapedics chairman and general partner at OrbiMed
Koblish currently serves as president and chief executive officer of Tela Bio,
Inc., a privately-held company located outside Philadelphia, Pennsylvania
focused on surgical reconstruction products.
Koblish most recently held the position of president of Stryker
Orthobiologics, the business unit formed following the acquisition of
Orthovita, Inc. by Stryker Corporation in June 2011 for $316 million. Koblish
previously served as president and chief executive officer of Orthovita, Inc.
and under his leadership established a 100-person strong direct US sales force
and grew revenue from $4 million to approximately $100 million. Prior to being
appointed to that position in April 2002, he held various other positions at
Orthovita including senior vice president of commercial operations and
managing Orthovita’s worldwide marketing division. Prior to his service at
Orthovita, Koblish served as director of marketing and product development for
the reconstructive specialty group of Howmedica, Inc., a subsidiary of Pfizer,
Koblish earned a bachelor of science degree in mechanical engineering from
Worcester Polytechnic Institute and a master of science degree in mechanical
engineering and applied mechanics from the University of Pennsylvania.
“Tony brings a wealth of experience to Cerapedics - from achieving product
approvals at FDA to launching and selling innovative biologic products in the
orthopedics marketplace. He also has significant insights that come from
running a successful market-leading biologics company for over a decade. He
will be a tremendous addition to our board,” said Paul Mraz, Cerapedics
president and chief executive officer.
“I am honored to join the Cerapedics board of directors and work with this
exceptional team,” Koblish said. “Our goal is for Cerapedics to be a leader in
the global bone biologics market and I look forward to sharing my knowledge
with and contributing to the future direction and growth of Cerapedics.”
About Cerapedics, Inc.
Cerapedics, a 2012 Colorado Companies to Watch (COCTW) winner, is a medical
device company focused on developing and commercializing novel osteobiologic
products based upon its proprietary synthetic small peptide (P-15™) technology
platform. i-FACTOR bone graft is the only biologic bone graft that utilizes a
small peptide as an attachment factor intended to stimulate the natural bone
healing process resulting in safe, predictable bone formation at a fraction of
the cost of growth factors.
CAUTION: i-FACTOR™ bone graft is not commercially available in the USA. In the
USA, i-FACTOR bone graft is an investigational device limited by Federal Law
(USA) to investigational use only.
More information can be found at www.cerapedics.com.
Steve McAdoo, +1-303-974-6275
Vice President of Marketing
Press spacebar to pause and continue. Press esc to stop.